Baiyunshan: Subsidiary's Xuhan Ting Granules Approved for New Clinical Trial in Children with Recurrent Respiratory Tract Infections

robot
Abstract generation in progress

Recently, Baiyunshan announced that its subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., has received the clinical trial approval notice for the additional indications of Xuhanting Granules.

Xuhanting Granules have the effects of benefiting qi and nourishing yin, stabilizing the exterior, and stopping sweating. They are used for spontaneous sweating, night sweats, and children’s night sweats caused by deficiency of qi and yin. This product is an already marketed traditional Chinese medicine compound preparation. The current application is for clinical trials to add use in children with recurrent respiratory infections.

As of the date of this announcement, Qixing Pharmaceutical has invested approximately 20.52 million yuan in research and development for Xuhanting Granules. In 2024, Qixing Pharmaceutical’s sales of Xuhanting Granules are expected to reach 49.09 million yuan.

(Baiyunshan Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin